Introduction
The association between arginine and citrulline, i.e. between asymmetric dimethylarginine (ADMA) as dimethyl derivative of the amino acid L-arginine and anti-cyclic citrullinated peptide antibodies (Anti-CCP 2 ) of the second generation in patients with Rheumatoid Arthritis (RA) is the isoform of the enzyme Peptidylarginine Deiminase (PAD). Enzymatic deimination or protein citrullination is a process catalyzed by PAD enzymes which take part in the pathogenesis of RA. [1, 2] In humans five PAD isoforms (PAD [1] [2] [3] [4] and PAD 6 ) are present. The greatest attention is paid to PAD 2 and PAD 4 , as potential candidates that could play role in the process of citrullination of autoantigens in RA. Both enzymatic forms are present in the rheumatoid synovium and fluid. [3] [4] [5] The polymorphism of PAD 4 is genetically associated with RA [6] . There is a difference in the tissue and cellular distribution of these two forms: PAD 2 is ubiquitously distributed in tissue (on the cytoplasmic level), while PAD 4 is more dominant in the hematopoietic cells (on nuclear level) [7] [8] [9] [10] [11] . In human neutrophils three different PAD isoforms (PAD [2] [3] [4] ) are expressed. PAD targets are different cells' substrates on cellular or sub-cellular level. In the process of intracellular protein citrullination, different auto-antibodies recognize these substrates as citrullinated substrates. But, this explanation is probably partial, because the protein citrullination can take place also extracellularly. Cellular targets, identified as potential citrullinated autoantibodies with extracellular distribution are: filaggrin, vimentin, β-actin, collagen type I and II, gamma enolase etc [12] [13] [14] [15] [16] [17] [18] [19] . Extracellular citrullination of fibrinogen is probably derived by PAD from damaged cells [4, 20] , but, so far it is not known in which conditions it occurs. Citrullinated autoantibodies play key role in the immune answer in RA. Few unique characteristics of protein citrullination enrolled in the pathogenesis of RA are identified: 1. The cytoplasmic content has autoantigenic features and is a target in the process of citrullination; 2. Although there are great number of proteins citrullinated by the active neutrophils, anti-CCP 2 recognises only small number of these molecules; 3. Citrulline activity of each PAD isoforms is characterized by the unique substrate specificity, independently of their subcellular distribution. Only PAD 2 is capable of citrullination of native β/γ actine, while H 3 hystones are only citrullinated by PAD 4 isoform. PAD 4 isoform which is cytoplasmic enzyme similar to PAD 2 is not able to citrullinate actine and H 3 hystone; 4. Different reactive abilities of different sera in RA support the hypothesis that anti CCP 2 antibodies recognize the unique sequence [2, 21] . The variations in the specificity of anti CCP 2 antibodies in different patients with RA are impressive. Probably all PAD isoforms share similar epitopes and their possible presence in the extracellular space indicate possible pass through the subcellular barriers.
Some Aspects of Dimethylarginine Derivatives of the Amino Acid L-Arginine
There are 2 stereoisomers of the L-arginine: symmetric (SDMA) and asymmetric dimethylarginine (ADMA). ADMA interferes with L-arginine in the production of nitric oxide (NO), which plays key role in the normal endothelial function. Namely, NO is synthesized in the endothelial cells with the enzyme -endothelial nitric oxide synthetase (NOS). The physiological substrate (precursor) for NOS in this enzymatic process is L-arginine, converted in NO and L-citrulline. The NOS is inhibited by ADMA. The plasma level of ADMA is elevated in RA.
ADMA is synthesized by protein methylation mostly in the cellular nucleus. The methylation is catalyzed by the group of enzymes called protein arginine N-methyl tranferases (PRMTs type I and II). Both PRMT subtypes have the ability to methylate monomethyl arginine (MMA); type 1 asymmetrically dimethylates arginine and creates ADMA, while type 2 catalyzes symmetrical dimethylation of arginine and creates SDMA (Figure 1 ).
Aim
The aim of this study is to determine the association between ADMA and anti-cyclic citrullinated peptide antibodies (Anti-CCP 2 ) of the second generation in patients with Rheumatoid Arthritis (RA) and to explain their connection in the process of citrullination of autoantigens in RA.
Material and methods
In the patients examined for this study, the diagnosis of the disease was established on the basis of revised diagnostic criteria for the classification of RA, suggested in 1987 by the American Association for Rheumatism (ARA) [22] . In order for a patient to be diagnosed with rheumatoid arthritis, patients must fulfill at least four out of seven criteria. Criteria from one to four are present for at least six month. In order to be included in the study every patient should fulfill at least 4 of the predicted 7 criteria. Criteria of diagnosis are related to American Colleague of Rheumatology (ACR).
In the study are included 70 patients, 35 patients with RA (28 women and 7 men), as well as 35 patients as healthy control group (18 women and 17 men). The mean age is 56, 68 years (±6.79) (40-65 years) in the group with RA and 46.2 years (±12.49) (29-65 years) in the healthy control group. The median duration of the disease in months is 43.97 (±45,23) in the interval of 1-168 months. Three patients were previously treated with oral steroids, while nobody was treated with NSAIDs. The others denied the use of other drugs such as arginine or nitroglycerin before the entrance in the study.
Inclusion criteria
In the study are included patients with RA aged 18-65 years, previously non-treated with NSAIDs or DMARDs.
Exclusion criteria
In the study are not included patients with diseases or conditions that could directly or indirectly influence the results, such as: previous history of spleen disease, thyroid disorders, hepatic damages, kidney, hematologic, neurologic and pulmonary disorders, autoimmune diseases, age <18 years; 2. Patients with Diabetes mellitus, acute infections, malignant diseases, febrile conditions ; 3. Patients with uric arthritis, urinary infections, SLE, mixed connective tissue disease, vasculitis; 4. Patients with previous history of blood trasfusions, as well as overweight patients; 5. Patients treated with basic drugs for RA are excluded from the study; 6. Also, patients with the presence of hypeglycemia and elevated level of degradation products (serum urea and creatinin, urine creatinin), smokers, patients with arterial hypertension, hematologic and enzymatic disorders detected in 0 point, are excluded from the study; 7. Patients treated with cardiologic and hypolipidemic drugs, oral contraceptive drugs (estrogens, progesterone), vitamin E, nitroclycerin, arginine or analogues, and patients who received inhalational anesthetics one month before the start of the study are also excluded.
All participants voluntarily participated in the study, so the ethic criteria for the preparation of the study were fulfilled.
clinical evaluation for disease activity
The clinical evaluation is made by the subspecialist in the field. Disease activity is evaluated using the DAS 28 index (Disease Activity Score (DAS 28 ). [23] The index uses mathematical formula in order to obtain unique composite quantitative score which consists of palpable painful joints (maximal number -28), swollen joints (maximal number -28), Westergren's Erythrocyte Sedimentation Rate (ESR) and patient's global evaluation for the disease activity (0-100 mm Visual Analogue Scale -VAS) as morning stiffness (in minutes). The DAS 28 index ranges from 0 to 10, and score bellow 3.2 qualifies the disease as low active. Reference range: <20 IU/ml in serum.
Laboratory evaluation
Quantitative method for determination of the ESR is the Westergren method.
Reference range: 7-8mm for men, 11-16 for women.
Statistical analysis
To test the significance of differences between two arithmetic means (proportions), the Student's t-test is used in comparison with the mean values of the determined numerical parameters between two groups, as well as Wilcoxon-matched test for independent specimens. The sensitivity and the prediction for the positive and negative test of the examined markers are determined with the test for sensitivity and specificity. The P-value in the range 0.05 and 0.1 is considered statistically significant. The data processing is made with the statistical package -Statistica 7.0. 
Results
Of the 35 patients with RA, 13 patients (37,14%) showed presence of ADMA. RF was present in 23 patients (65.71%). Of 18 RF negative patients, ADMA was detected in 9 patients (50%), while 11 patients (31,42%) were anti CCP 2 positive. In 17 RF positive patients ADMA was present in 4 patients; 12 patients (34,28%) were anti CCP 2 and RF positive. In the healthy control group 8 patients (22,85%) showed ADMA positivity. RF was present in 2 patients (5,71%), while 1 patient (2,85%) showed anti CCP 2 positivity. In 35 patients with RA, DAS 28 >3.2 was present in 28 patients (80%). In 17 seropositive RF patients, DAS 28 >3.2 was present in 15 patients (88,23%) ( Tables 1,2 ).
There is no statistical significance using Wilcoxon-matched test between ADMA in RA and the healthy control group for p<0.05 (p=0.555). 2. There is statistical correlation using Wilcoxon-matched test between ADMA in RA and age, duration of disease in months, DAS 28 index, RF and CRP, ESR, morning stiffness, in the same group for p<0.05: (ADMA vs age p=0.000; ADMA vs duration of disease in months p=0.000; ADMA vs DAS 28 p=0,000; ADMA vs RF p=0,018; ADMA vs CRP p=0,040; ADMA vs ESR p=0,000). 3. Although the presence of anti CCP 2 positive patients in DAS 28 >3.2 seropositive and seronegative patients is almost the same (10 vs 9 patients), the range of anti CCP 2 titre is higher in 10 RF seopositive patients with DAS 28 >3.2 than in RF seronegative patients with DAS 28 >3.2 (2.23 ± 0.61vs1.92 ± 0.45). There is no statistical correlation between these two groups (p=0.374) (Chart 1). 4. There is statistical correlation using Wilcoxon-matched test between anti CCP 2 in RA and the healthy control group for p<0.05 (p=0.000), as well as between anti CCP 2 in RA and DAS 28 , RF, CRP, ESR and morning stiffness in the same group for p<0.05 (anti CCP 2 vs DAS 28 p=0,000; anti CCP 2 vs RF p=0,018; anti CCP 2 vs CRP p=0,041; anti CCP 2 vs ESR p=0.000, anti CCP 2 vs morning stiffness p=0,000). There is moderate correlation between ADMA and anti CCP 2 antibodies in the group of patients with RA (r=0.34) (Chart 2).
Discussion
The ADMA activity in serum is normally low. It is elevated in endothelial dysfunction, because of the presence of the chronic inflammation in RA. Its presence is quantified by the degree of inflammation in RA which correlates with the disease activity. There is a strong correlation between ADMA and anti-CCP 2 antibodies from the second generation in early RA as a result of the disease activity and chronic inflammation [24] [25] [26] .
Seropositivity influences the ADMA induction (present also in our case) -seropositive RF patients with DAS 28 >3.2 have higher ADMA induction than seronegative RF patients with DAS 28 >3.2.
The association between ADMA and anti CCP 2 antibodies in patients with RA is confirmed also by other authors. They confirm the hypothesis that ADMA accumulation is associated with elevated titer of anti CCP 2 antibodies. Their conclusion is that excessive ADMA accumulation is associated with elevated titer of anti CCP 2 antibodies in patients with RA which duration is less than 3 years [25] .
The association between anti CCP 2 antibodies and RF IgM in patients with RA and their predictive value is shown by other authors [27] . They conclude that anti CCP 2 antibodies and RF IgM are associated with the impaired endothelial function, independently from other cardiovascular risk factors. These autoantibodies could be reflection of the early atherosclerotic conditions and can induce increased risk of cardiovascular diseases.
The process of citrullination is desribed by other authors, also [28] . They demonstrate that human PAD 4 regulates the histone arginine methylation through conversion of methyl arginine in citrulline, releasing methylamine. The targets of PAD 4 are multiple areas in H 3 and H 4 histones that are methylated by the co-activators CARM 1 ). The decrease of the histone arginine methylation is secondarily associated with the increase in the process of citrullination. They point out that PAD 4 is mediated by the genetic expression through the regulation of arginine methylation and histone citrullination.
Other authors have almost equal perception [29] . They emphasize that PAD enzymes catalyze the conversion of arginine residues in proteins with citrulline residues. The citrulline is not a standard amino acid. It is not incorporated in proteins during translation, but is generated post-translationally by PAD enzymes. In normal conditions only nuclear histones possess this amino acid.
Other authors also agree with the principle of auto-antigenicity in RA [30] . They relate auto-antigenic citrullination and different PAD enzymes in RA, emphasizing that PAD enzymes have intrinsic capacity for selection of protein targets. Such specificity could play role in auto-antigenic selection in RA. Other authors [31] [32] [33] conclude that citrullination of the proteins is enabled with the enzymatic conversion (by PAD enzyme) from proteins that contain arginine residues towards citrulline residues. They agree that PAD enzymatic activity fulfill the criteria as additive marker in monitoring disease progression, together with anti CCP 2 and RF. They emphasize that the PAD method for detection is rapid, sensitive and relatively cheap.
They suggest that citrullination and methylation of the arginine residues is a process of competition. It is theoretically reversible in regard of methylation of arginine residues through conversion of mono-methyl-peptydyl-arginine (MMA) in citrulline. But, contradictory results are shown in terms of the capacity of the PAD enzymatic activity towards citrullination of MMA. In regard of the reversibility of the arginine methylation, in general, the protein methylation is one-way process and the methylated arginine residues rest as an integral part of the proteins so far, until they are degraded in the process of proteolysis. The protein methylation, generally, is considered as an irreversible process, due to the lost of demethylating enzymes in the process of conversion.
PAD 4 is not able to citrullinate directly ADMA, but, it interferes in ADMA synthesis via citrullination of MMA as an intermediary product in ADMA synthesis.
Conclusion
ADMA is indirectly linked between autoantigenic citrullination and peptydyl-arginines' enzymatic isoforms in RA. Determination of ADMA together with other biological parameters contributes in the early diagnosis of RA.
